Several studies have linked activation of c-MET signalling to phosphorylation of intracellular signalling cascades such as PI3K/AKT, MAPK/ERK [34, 35] or FAK [36] in pancreatic cancer models, leading to tumor cell invasiveness, motility and resistance to gemcitabine therapy. This evidence concerns the gene PTK2 and familial pancreatic carcinoma.